Please enter the email address you used to register, then we will send you a link to choose a new password
Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Strong Buy rating and an...
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate o...
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate o...
William Blair analyst Lachlan Brown initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Outperform rating.